MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.semarthrit.2025.152640

Медицинская библиотека · Seminars in arthritis and rheumatism · 2025

Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice.

Martín-Gutiérrez Adrián, Loricera Javier, Aldasoro Vicente, Maiz Olga, de Miguel Eugenio, Galíndez-Agirregoikoa Eva, Ferraz-Amaro Iván, Castañeda Santos, Blanco Ricardo, Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Tocilizumab (TCZ) is the only biologic approved in Giant Cell Arteritis (GCA). In clinical trials around a quarter of patients relapse during TCZ treatment. We assess the frequency, features and factors associated with relapses in a wide series of GCA patients in a real-world setting.

METHODS

National multicenter observational study of GCA patients treated with TCZ between 2016 and 2021. The variables collected at TCZ initiation were demographic, clinical, laboratory, temporal artery biopsy, and imaging findings, corticosteroids dose, previous therapies and TCZ therapeutic schedule. We perform a comparative study between patients with/ without relapses (bivariate analysis) and a study of factors associated with relapse (multivariate logistic).

RESULTS

We study 407 patients (295 women; mean age 73.6 ± 8.9 years). After a mean follow-up of 25.3 ± 21.7 months, relapses were observed in 63 of 407 (15.5 %) patients. At TCZ initiation, no differences were observed between both groups (with/without relapses) in demographic, clinical and laboratory features or corticosteroid dose. The median time to the first relapse was 12 [6-24] months being the most frequent manifestations polymyalgia rheumatica (47.6 %), and headache (12.7 %). In multivariate logistic regression analysis, the set of variables associated with GCA relapses were TCZ initiation later than 6 weeks (OR 3.446 [1.196- 9.931]), optimization (OR 2.803 [1.507-5.215]) and administration of IV TCZ (OR 2.327 [1.244-4.353]) and previous therapies to TCZ (OR 5.062[2.402-10.665]).

CONCLUSION

In this series, GCA relapses were observed in 15 % of patients, all of them non-severe. Relapses were associated with TCZ therapeutic schedule, such as IV administration, optimization, delayed initiation and previous therapies to TCZ.

Для цитирования: Martín-Gutiérrez Adrián, Loricera Javier, Aldasoro Vicente, Maiz Olga, de Miguel Eugenio, Galíndez-Agirregoikoa Eva, Ferraz-Amaro Iván, Castañeda Santos, Blanco Ricardo, Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice.. Seminars in arthritis and rheumatism. 2025. DOI: 10.1016/j.semarthrit.2025.152640.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.